Trump announces trade deal with EU following months of negotiations
Laboratory Corporation of America (NYSE:LH) Holdings, widely known as LabCorp, has reached a new 52-week high, with its stock price soaring to $258.7. With a market capitalization of $21.6 billion and a year-to-date return of 12.16%, the company has demonstrated strong momentum. According to InvestingPro data, analysts maintain a bullish outlook with price targets ranging from $248 to $300. This milestone underscores a period of significant growth for the healthcare diagnostics company, reflecting a substantial 30.86% increase over the past year. Investors have shown increased confidence in LabCorp’s business model and its ability to capitalize on the expanding market for medical testing and diagnostics, which has been further accelerated by the company’s strategic initiatives and partnerships. The impressive one-year change in LabCorp’s stock value highlights the company’s resilience and adaptability in a dynamic healthcare landscape. Based on InvestingPro’s Fair Value analysis, the stock appears slightly overvalued at current levels, though the company maintains a "GOOD" overall financial health score. For deeper insights and additional ProTips, explore LabCorp’s comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, LabCorp Holdings Inc. reported its Q1 2025 earnings, showing a revenue increase to $3.3 billion, which is a 5.3% year-over-year growth but below the forecasted $3.41 billion. The company achieved an adjusted earnings per share (EPS) of $3.84, slightly surpassing the expected $3.78. Additionally, LabCorp shareholders approved the 2025 Omnibus Incentive Plan and the 2025 Employee Stock Purchase Plan, promoting employee stock ownership. At the company’s recent Annual Meeting, directors were elected, and Deloitte & Touche LLP was ratified as the independent auditor for 2025. Mizuho (NYSE:MFG) Securities maintained an Outperform rating for LabCorp and raised the stock target to $274, reflecting confidence in the company’s earnings visibility. Furthermore, LabCorp continues to focus on high-growth areas such as oncology and women’s health, aiming for $100-$125 million in cost savings through its Launchpad initiative. Despite the revenue miss, LabCorp reaffirmed its revenue and free cash flow guidance for 2025, with expectations of margin expansion across its segments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.